[Skip to Content]
[Skip to Content Landing]
Article
July 6, 1957

MISCELLANY

Arthur R. Colwell Sr., M.D.; Dwight Ingle, Ph.D.; Maurice Krahl, Ph.D.; et al Rachmiel Levine, M.D.; Henry T. Ricketts, M.D.; Informational Committee on Oral Hypoglycemic Compounds American Diabetes Association, Inc.
JAMA. 1957;164(10):1151-1152. doi:10.1001/jama.1957.02980100107019
Abstract

CLINICAL USE OF TOLBUTAMIDE IN DIABETES MELLITUS 

A STATEMENT BY THE AMERICAN DIABETES ASSOCIATION  Tolbutamide (Orinase), a hypoglycemic agent for oral use, recently has been released by the Food and Drug Administration and is being generally distributed for use by prescription. This statement by the American Diabetes Association confirms in virtually every detail the editorial which appeared in a recent issue of The Journal.1 Members of the medical and allied professions should be fully informed concerning this new drug.It is a sulfonylurea compound with the empirical formula C12H18N2O3S. It lowers the blood sugar level of normal animals and man and of some, but not all, diabetic patients. The mechanism involved is still unknown, but it seems clear that it is ineffective in the complete absence of insulin; hence, it cannot be considered a true substitute for insulin.According to the

First Page Preview View Large
First page PDF preview
First page PDF preview
×